1. Home
  2. LFVN

as of 11-11-2026 1:41pm EST

$4.80
+$0.24
+5.26%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of in the United States, Mexico, Canada, Japan, Taiwan, Thailand, Australia, New Zealand, the United Kingdom, the Netherlands, Germany, Austria, Spain, Ireland, Belgium, and Others. The company operates in a single operating segment by selling products directly to customers through an international network of independent consultants that operate in an integrated manner.

Founded: N/A Country:
United States
United States
Employees: N/A City: LEHI
Market Cap: 78.0M IPO Year: 1996
Target Price: $7.00 AVG Volume (30 days): 23.9K
Analyst Decision: Buy Number of Analysts: 2
Dividend Yield:
4.24%
Dividend Payout Frequency: semi-annual
EPS: -0.02 EPS Growth: -46.67
52 Week Low/High: $3.90 - $11.71 Next Earning Date: 11-09-2026
Revenue: $203,204,000 Revenue Growth: 1.86%
Revenue Growth (this year): -14.5% Revenue Growth (next year): 3.99%
P/E Ratio: -243.50 Index: N/A
Free Cash Flow: 6.7M FCF Growth: +0.14%

Stock Insider Trading Activity of Lifevantage Corporation (Delaware) (LFVN)

Cunningham Kristen

Chief Sales Officer

Sell
LFVN Sep 14, 2026

Avg Cost/Share

$6.18

Shares

8,901

Total Value

$55,008.18

Owned After

120,162

SEC Form 4

Cunningham Kristen

Chief Sales Officer

Sell
LFVN Sep 11, 2026

Avg Cost/Share

$6.41

Shares

100

Total Value

$641.00

Owned After

120,162

SEC Form 4

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K SELL

Nov 9, 2026 · 100% conf.

AI Prediction SELL

1D

-8.22%

$4.96

Act: -13.43%

5D

-10.37%

$4.84

20D

-3.15%

$5.23

Price: $5.40 Prob +5D: 0% AUC: 1.000
0001193125-26-453570

EX-99.1

2 lfvn-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1 LifeVantage Announces Financial Results for the First Quarter Fiscal 2027

Salt Lake City, UT, November 9, 2026, LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its quarter ended September 30, 2026.

First Quarter Fiscal 2027 Summary*:

• Revenue was $37.1 million, a decrease of 22.0% from the prior year period;

• Revenue in the Americas decreased 22.2%, and revenue in Asia/Pacific & Europe decreased 21.2%;

• Net loss per diluted share was $0.02, versus net income per diluted share of $0.17 a year ago;

• Adjusted earnings per diluted share was $0.05, compared to $0.18 a year ago; and

• Adjusted EBITDA was $1.9 million compared to $3.9 million a year ago.

* All comparisons are on a year over year basis and compare the first quarter of fiscal 2027 to the first quarter of fiscal 2026, unless otherwise noted.

“Despite a challenging quarter, LifeVantage has significant untapped potential, and we now have a clear strategy designed to capture it,” said Terrence Moorehead, President and Chief Executive Officer. “Our focus is on transforming LifeVantage into a more brand-driven, consumer-focused company, supported by a modern digital platform and an expanding community of consumers and brand advocates. At the same time, we are creating a more focused and efficient operating model and strengthening the underlying economics of the business. We have a lot of work to do, and building the company we envision will take time, but we have a differentiated foundation, a clear roadmap and a strong sense of urgency around execution. The actions we are taking are designed to build a stronger, more relevant LifeVantage and create sustainable long-term value for our shareholders.”

First Quarter Fiscal 2027 Results

For the first quarter ended September 30, 2026, the Company reported revenue of $37.1 million, a 22.0% decrease compared to revenue of $47.6 million in the quarter ended September 30, 2025, including a $0.4 million, or 0.8% negative impact from foreign currency. Revenue in the Americas region decreased 22.2% to $29.0 million. Revenue in the Asia/Pacific & Europe region decreased 21.2% to $8.2 million, including a $0.4 million, or 3.9%, negative impact from foreign currency. The decrease in revenue was primarily driven by lower active accounts, reflecting impacts from the broader macro environment, as well as lower sales of the MindBody GLP-1 System®. These declines were partially offset by sales of the LoveBiome product line, which the Company acquired in October 2025.

Gross profit for the quarter was $28.0 million, or 75.4% of revenue, compared to $37.8 million, or 79.5% of revenue, for the prior year period. The decrease in gross profit as a percentage of revenue was primarily due to an allowance for inventory obsolescence related to the MindBody GLP-1 System®, along with increases in shipping and warehouse related expenses. Adjusted for the allowance for inventory obsolescence, non-GAAP gross profit was $29.0 million, or 78.2% of revenue.

Commissions and incentives expense for the quarter was $15.4 million, or 41.4% of revenue, compared to $20.7 million, or 43.5% of revenue, for the prior year period. The decrease in commissions and incentives expense as a percentage of revenue compared to the prior year period is primarily due to the timing and magnitude of promotional and incentive programs, changes in revenue mix, and changes in the mix of customers and independent consultants.

Selling, general and administrative (SG&A) expense for the quarter was $12.7 million, or 34.3% of revenue, compared to $14.9 million, or 31.2% of revenue, for the prior year period. The increase in SG&A expense as a percentage of revenue reflects the overall decrease in revenue.

Operating loss for the quarter was $0.1 million compared to operating income of $2.3 million for the prior year period. Adjusted non-GAAP operating income for the quarter was $0.9 million compared to adjusted non-GAAP operating income of $2.5 million for the prior year period.

Net loss for the quarter was $0.2 million, or $0.02 per diluted share, compared to net income of $2.2 million, or $0.17 per diluted share, for the prior year period. Adjusted non-GAAP net income for the quarter was $0.6 million, or $0.05 per diluted share, compared to adjusted non-GAAP net income of $2.3 million, or $0.18 per diluted share, in the prior year period.

Adjusted EBITDA was $1.9 million, or 5.2% of revenue, for the quarter, versus $3.9 million, or 8.2% of revenue, for the prior year period.

Balance Sheet & Liquidity

The Company generated $0.5 million of cash from operations during the three months ended September 30, 2026 compared to $2.3 million used in operations in the prior year period, primarily reflecting decreases in accounts receivable, inventory, and oth

2026
Q2

Q2 2026 Earnings

8-K BUY

Aug 27, 2026 · 100% conf.

AI Prediction BUY

1D

+1.11%

$6.52

Act: -4.88%

5D

+12.96%

$7.29

20D

+21.38%

$7.83

Price: $6.45 Prob +5D: 100% AUC: 1.000
0001193125-26-371265

EX-99.1

2 lfvn-ex99_1.htm

EX-99.1

EX-99.1

LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2026

Salt Lake City, UT, August 27, 2026, LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its fourth fiscal quarter ended June 30, 2026.

Fourth Quarter Fiscal 2026 Summary*:

• Revenue was $42.4 million, a decrease of 23.1% from the prior year period;

• Revenue in the Americas decreased 24.8%, and revenue in Asia/Pacific & Europe decreased 16.9%;

• Net income per diluted share was $0.10, versus $0.15 per diluted share a year ago;

• Adjusted earnings per diluted share was $0.11, compared to $0.17 a year ago; and

• Adjusted EBITDA was $2.7 million compared to $4.8 million a year ago.

* All comparisons are on a year over year basis and compare the fourth quarter of fiscal 2026 to the fourth quarter of fiscal 2025, unless otherwise noted.

Fiscal Year 2026 Summary*:

• Revenue was $182.6 million, a decrease of 20.1% from the prior year period;

• Revenue in the Americas decreased 23.2%, and revenue in Asia/Pacific & Europe decreased 6.9%;

• Net income per diluted share was $0.40, versus $0.75 per diluted share a year ago;

• Adjusted earnings per diluted share was $0.56, compared to $0.82 a year ago; and

• Adjusted EBITDA was $13.7 million compared to $22.1 million a year ago.

* All comparisons are fiscal year 2026 to fiscal year 2025.

"It's a privilege to lead LifeVantage at this stage of its journey and my conviction about this Company is stronger today than when I accepted the role," said Terrence Moorehead, President and Chief Executive Officer. "With a differentiated, science-backed platform, strong gross margins and a debt-free balance sheet, our foundation is strong and I believe we have a real competitive advantage. Our early focus will be on strengthening the LifeVantage brand, building a more relevant consumer proposition, and driving operational excellence. Despite the challenges reflected in our recent results, I'm optimistic about what lies ahead. We intend to move forward with a real sense of urgency and look forward to sharing more about our strategy as our work progresses."

Fourth Quarter Fiscal 2026 Results

For the fourth quarter ended June 30, 2026, the Company reported revenue of $42.4 million, a 23.1% decrease compared to revenue of $55.1 million in the fourth quarter of fiscal 2025. Revenue in the Americas region decreased 24.8% and revenue in the Asia/Pacific & Europe region decreased 16.9%. These decreases were primarily due to due to downward pressure in the number of orders from our active account base and lower average order size, reflecting impacts from the broader macro-economic environment, as well lower sales of our MindBody GLP-1 System cycling the higher comparable fourth quarter of fiscal 2025, partially offset by sales of LoveBiome, which we acquired in October 2025.

Gross profit for the fourth quarter of fiscal 2026 was $33.0 million, or 78.0% of revenue, compared to $44.0 million, or 79.9% of revenue, for the same period in fiscal 2025. The decrease in gross profit as a percentage of revenue was primarily due to a shift in product mix, inventory obsolescence expenses, and increases in shipping related expenses.

Commissions and incentives expense for the fourth quarter of fiscal 2026 was $17.5 million, or 41.3% of revenue, compared to $23.2 million, or 42.1% of revenue, for the same period in fiscal 2025. The decrease in commissions and incentives expenses as a percentage of revenue compared to the prior year period is primarily due to the timing and magnitude of promotional and incentive programs and changes to the sales mix between customers and independent consultants.

Selling, general and administrative (SG&A) expense for the fourth quarter of fiscal 2026 was $13.9 million, or 32.7% of revenue, compared to $18.7 million, or 33.9% of revenue, for the same period in fiscal 2025. The decrease in SG&A expenses as a percentage of revenue was primarily due to decreases in variable employee compensation expenses and lower event related expenses.

Operating income for the fourth quarter of fiscal 2026 was $1.7 million compared to $2.1 million for the same period in fiscal 2025. Adjusted non-GAAP operating income for the fourth quarter of fiscal 2026 was $1.8 million compared to adjusted non-GAAP operating income of $2.5 million for the same period in fiscal 2025.

Net income for the fourth quarter of fiscal 2026 was $1.3 million, or $0.10 per diluted share, compared to $2.0 million, or $0.15 per diluted share for the same period in fiscal 2025. Adjusted non-GAAP net income for the fourth quarter of fiscal 2026 was $1.4 million, or $0.11 per diluted share, compared to adjusted non-GAAP income of $2.3 million, or $0.17 per diluted share, in the same period of fiscal 2025.

Adjusted EBIT

2026
Q1

Q1 2026 Earnings

8-K SELL

May 6, 2026 · 100% conf.

AI Prediction SELL

1D

-8.03%

$5.52

Act: -16.33%

5D

-10.84%

$5.35

Act: -12.17%

20D

-11.51%

$5.31

Act: +55.17%

Price: $6.00 Prob +5D: 0% AUC: 1.000
0001193125-26-208934

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.c706d217.1784333952.ccc6866f

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

Share on Social Networks: